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1. Introduction 2.2. Preparation of monoclonal hybridoma cell lines 
Guanylate cyclase (GTP pyrophosphate-lyase, 
cyclizing, EC 4.6 .1.2), the enzyme responsible for the 
synthesis of cyclic GMP, is detected mostly in soluble 
fraction and partly associated with particulate fraction 
of mammalian tissues [l-61. In rat brain, guanylate 
cyclase is found mainly in synaptosomal soluble frac- 
tion suggesting its involvement in the neural transmis- 
sion [6]. We have purified the soluble guanyiate 
cyclase from bovine brain to an apparent homogeneity 
and produced the antibody to the enzyme by immu- 
nizing a rabbit [7]. The antibody effectively inhibited 
the soluble guanylate cyclase activity from various 
mammalian tissues, but not the Triton-dispersed par- 
ticulate guanylate cyclase from tissues. 
A method for preparing amonoclonal antibody 
has been established [8]. Because of its high specificity, 
a monoclonal antibody would offer a method for 
studying the different properties of enzyme molecules 
and for histochemically demonstrating the cellular as 
well as subcellular localization of guanylate cyclase. 
We report here production and properties of the 
monoclonal antibody to the soluble guanylate cyclase 
of rat brain. 
The purified guanylate cyclase (64OMg) was injected 
into BALB/c mouse intraperitoneally with 2 X lo9 
heat-inactivated pertussis organisms. The booster 
injections were carried out twice at a 3-week interval 
without pertussis organisms. Spleen cells were taken 
from immunized mouse 3 days after the last booster 
injection and fused with mouse myeloma cells P3-NS 
I/l-Ag4-1 (NS I) as in [9]. Spleen cells (1.6 X 108) 
were fused with 4 X 10’ myeloma cells by the addi- 
tion of 1 ml 50% polyethylene glycol4000. The cells 
were suspended in growth medium (RPM1 1640 sup- 
plemented with 15% fetal bovine serum, 2 mM L-glu- 
tamine and 1 mM pyruvate) and inoculated in two 
96-well Nunc Microtest Plates. Two days later, 0.1 ml 
of HAT selective medium (growth medium supple- 
mented with 100 PM hypoxanthine, 0.4 PM amino- 
pterin and 16 PM thymidine) was added and half of 
the medium was replaced 3 times during the subse- 
quent 10 days. Fourteen days after cell fusion, culture 
fluid (60 fl) was assayed for anti-guanylate cyclase 
antibody by measuring enzyme inhibition as described 
below. Monoclonal hybridoma cell lines were obtainec’ 
by a limiting dilution method repeated twice. 
2.3. Inhibition assay of guanylate cychzse activity 
2. Materials and methods 
2.1. IZtrification ofguanylate cyclase 
Guanylate cyclase was purified from supernatant 
fraction (300 X g) of rat brain by pH precipitation, 
(NH&SO4 fractionation, phenylSepharose, DEAE- 
Sepharose and Sephacryl S-300 columns as described 
in [7]. The specific activity of the enzyme prepara- 
tion was 97 nmol cyclic GMP formed . min-‘. mg pro- 
tein-‘. The purified guanylate cyclase was stored at 
-8O’C until use. 
Enzyme preparation was preincubated with anti- 
guanylate cyclase IgG at 4’C for 12 h in a total volume 
of 0.1 ml. Goat antimouse IgG (I 5 Erg) was then 
added and incubated at 4’C for 1 h. The resulting 
precipitate was removed by centrifugation at 
105 000 X g for 30 min, and the supernatant fluid 
was assayed for guanylate cyclase activity. Guanylate 
cyclase activity was assayed as in [lo]. 
2.4. Immunochemical titration 
Immunochemical titration was performed by a 
mblished by Elsevier Biomedical Press 
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modification of the method in [ 1 I]. Rat tissues were 
homogenized with 5 volumes of 25 mM Tris-HCl 
(pH 7.6) and centrifuged at 105 000 X g for 1 h. 
Varying amounts of the supernatant were incubated 
with 1.92 E.cg I G in a total volume of 80 111 at 4°C for 
12 h. Then, 10 ~1 of 10% (v/v) suspension of heat- 
inactivated StaphyZococc~~ aureus [ 121 was added 
and incubated at 4’C for 1 h. The resulting precipitate 
was removed by centrifugation, and the supernatant 
fluid was assayed for guanylate cyclase activity. 
3. Results and discussion IgG fraction added ( JJ 9 1 
Seven out of 190 proliferating hybridomas secreted 
anti-guanylate cyclase antibody as determined by the 
double antibody precipitation method. Four cell 
lines with a high titer of antibody were chosen for 
cloning by limiting dilution method. After repeated 
subcloning, seven stable hybridoma clones producing 
antibody to soluble guanylate cyclase were obtained. 
The clone (7-B7) of the highest iter of antibody was 
used in the following experiments. When the super- 
natant of rat brain was preincubated with the mono- 
clonal antibody and the enzyme-antibody complex 
was removed by the addition of goat antimouse IgG 
followed by centrifugation, guanylate<yclase activity 
in the supernatant markedly decreased (fig.1 A). 
Approximately 50% inhibition occurred with 3 @g IgG, 
which was 50-fold more active than rabbit polyclonal 
antibody prepared in [7]. However, when the super- 
natant of rat brain was incubated with the antibody 
alone, guanylate cyclase activity was inhibited by 
only 30%, indicating that the antibody reacted with 
the enzyme without blocking the catalytic site. The 
antibody did not affect the activity of guanylate 
cyclase solubilized from the synaptic membrane frac- 
tion of rat brain. 
Fig.1. Titration curves of monoclonal antibody vs various 
enzyme preparations. (A) Supernatant (e and o) or Triton- 
dispersed synaptic membrane fraction (A) of rat brain was 
prelncubated with various quantities of monoclonal antibody 
at 4°C for 12 h. Goat antimouse IgG (1.3 ng/Mg of mono- 
clonal antibody) was then added and incubation was continued 
at 4’C for 1 h. The enzyme-antibody complex was then 
removed by centrifugation, and the supernatant was assayed 
for guanylate cyclase activity (0 and A). Another series of 
brain supernatant was assayed without addition of goat anti- 
mouse IgG and centrifugation (0). (B) Rat brain supernatant 
(e), rat lung supematant (0) or mouse brain supernatant (A) 
was used as an enzyme preparation. Assays were performed 
as described above. The values are the means of duplicate 
determinations. 
Table 1 
Effect of monoclonal antibody on soluble guanylate cyclase 
from various tissues of rat 
Tissues Guanylate cyclase activity 
(pmol/assay) 
% activity of 
control IgG 
The antibody inhibited guanylate cyclase activity 
in the supernatants of brain, liver, lung and heart of 
rat (fig.1 B and table l), while the soluble enzyme 
from the brains of mouse, rabbit, chick and monkey, 
and from neuroblastoma NlE 115 cells was not inhib- 
ited by the antibody (tig.lB and table 2). A 70% inhi- 
bition was observed with the soluble guanylate cyclase 
from bovine brain. 
Brain 
Liver 
Lung 
Heart 
+Control IgG +Monoclonal IgG 
360 12.2 3.4 
368 24.1 6.1 
338 34.4 10.1 
315 11.0 3.5 
The guanylate cyclase activity per unit enzyme 
protein was compared in various tissues of rat by an 
immunochemical titration method using the mono- 
clonal antibody. A fured amount of the antibody 
(1.92 E.cg) was incubated with various amounts of the 
Rat tissues were homogenized with 5 volumes of 25 mM 
Tris-HCl (pH 7.6) and centrifuged at 105 000 x g for 1 h. 
The supematant was adjusted to pH 5.2 and resulting precip- 
itate was collected by centrifugation and dissolved in 25 mM 
Tris-HCl (pH 7.6). Enzyme activity/volume was adjusted to 
the same level among various tissues. The enzyme preparations 
were preincubated with 10 pg of monoclonal antibody at 
4°C for 12 h. Goat antimouse IgG (13 ccg) was then added 
and incubation was continued at 4°C for 1 h. The enzyme- 
antibody complex was removed by centrlfugation, and the 
supernatant was assayed for guanylate cyclase activity. The 
values are the means of duplicate determinations 
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Table 2 
Effect of monoclonal antibody on soluble guanylate cyclase from brains of 
various vertebrates 
Species Guanylate cyclase activity % activity of 
(pmol/assay) control IgG 
Rat 
Mouse 
Rabbit 
Chick 
Bovine 
Monkey 
Neuroblastoma 
NlE 115 
+Control IgG +Monoclonal IgG 
976 25 3 
1034 905 88 
1709 1519 89 
1133 961 85 
1122 365 32 
1162 1126 97 
1021 95 
Preparation and assay of soluble guanylate cyclase from the brains of various ani- 
mals were performed as described in table 1. The values are the means of duplicate 
Supernatant ( p I ) 
Fig.2. Immunochemical titration of soluble guanylate cyclase 
of rat tissues. Synaptosomal soluble fraction (0) and the 
supernatants of brain (o), liver (A), heart (A) and lung (v) of 
rat were used as enzyme preparations. The experiment was 
performed as in section 2. The values are the means of tripli- 
cate determinations. 
enzyme preparations of tissues followed by removal 
of the enzyme-antibody complex and the remaining 
enzyme activity in the supernatant was determined 
(fig.2). From the intercepts of abscissa nd the slopes 
of the activity, the guanylate cyclase activity bound 
to 1 pg of IgG was calculated (table 3). The activities 
of synaptosomal soluble fraction and lung supematant 
were 29- and 4-fold higher than those of the superna- 
tants of brain, liver and heart, respectively. However, 
when guanylate cyclase was precipitated from the 
synaptosomal soluble fraction at pH 5.2 and dialyzed, 
the enzyme activity bound to 1 pg of IgG decreased 
to 7.8 pmol/lO min, which was comparable to those 
of the supernatants of brain, liver and heart. The 
observation i dicates that the guanylate cyclase in the 
synaptosomal soluble fraction of rat brain is in a highly 
activated state, and is consistent with our previous 
Table 3 
Immunochemical titration of soluble guanylate cyclase of 
rat tissues 
Tissues Guanylate cyclase activity 
bound to 1 pg antibody 
(pmol/l 0 min) 
Brain 9.9 
Lung 36.5 
Liver 9.9 
Heart 7.3 
Synaptosomal soluble fraction 289 
The guanylate cyclase activities bound to 1 pg IgG were cal- 
culated from the intercepts of abscissa nd the slopes of activ- 
ity in fig.2 
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finding that synaptosomal soluble fraction contained 
an endogenous activator for guanylate cyclase [6,13]. 
The observation also coincided with the reports that 
activating factors were present in the supernatant of
rat lung [ 14,151. 
We have previously prepared the antibody to 
soluble guanylate cyclase purified from bovine brain 
by immunizing a rabbit [ 71. The antibody cross-reacted 
with the soluble enzyme from various tissues of rat, 
mouse, bull and neuroblastoma cells, but did not 
react with the particulate nzyme of various tissues. 
The monoclonal antibody to the soluble guanylate 
cyclase from rat brain also reacted with the soluble 
enzyme from rat tissues, but not with the particulate 
guanylate cyclase of synaptic membrane, indicating 
that particulate nzyme is immunologically distinct 
from soluble nzyme. We have obtained 7monoclonal 
antibodies, all of which exhibited the same properties 
as the clone (7-B7) reported here. Garbers has shown 
that the antibody to the particulate guanylate cyclase 
from sea urchin inhibited the particulate nzyme from 
rat tissues, but not the soluble nzyme from rat tissues 
[ 161. The differing properties between soluble and 
particulate guanylate cyclase have been indicated by 
the difference in kinetics [5,17], metal requirement 
[ 5 ,17-l 91, apparent Mr [ 17,201 and the sensitivity 
to proteolysis [21,22]. On the other hand, Zwiller 
et al. reported that the antibody to soluble guanylate 
cyclase of rat brain they prepared cross-reacted with 
particulate nzyme, indicating apartial similarity 
between soluble and particulate guanylate cyclase [231. 
Lewicki et al. have recently reported the produc- 
tion of monoclonal antibodies to soluble guanylate 
cyclase from rat lung [24,25]. Their antibodies recog- 
nized the soluble lung enzymes from rat, beef and pig, 
but did not, or only slightly cross-reacted with the 
soluble enzymes from rabbit and mouse lung [25]. 
The monoclonal antibody prepared here a&o discrim- 
inates between soluble enzymes of rat and other spe- 
cies of vertebrates, indicating that soluble guanylate 
cyclases from different species of animals contain a 
different structure in the enzyme proteins. A specific 
monoclonal antibody with a very high titer would 
enable us to study the protein structure of the enzyme 
and the localization of soluble guanylate cyclase in 
tissues immunohistochemically. 
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